Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 13Terminated 4Recruiting 3Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Gastrointestinal 1

Conditions

Prostatic Neoplasms 2Urogenital Neoplasms 1Gastric Adenocarcinoma 1Erectile Dysfunction 1

Interventions

pembrolizumab 563Specimen Handling 493Carboplatin 451Magnetic Resonance Spectroscopy 444Cyclophosphamide 418Cisplatin 405Radiotherapy 353Bevacizumab 314Gemcitabine 313Paclitaxel 298Biopsy 292Drug Therapy 284Blood Specimen Collection 248Capecitabine 246Oxaliplatin 241fludarabine 239Nivolumab 234venetoclax 221Injections 213Docetaxel 211Fluorouracil 206Dexamethasone 188Radiosurgery 182Standard of Care 159Rituximab 159Pemetrexed 156Surgical Procedures, Operative 148atezolizumab 146durvalumab 145Leucovorin 140

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Tadalafil × Clear all
NCT05709574 2025-10-16

Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer

University of Arizona

Phase 2 Recruiting
10 enrolled
Gastrointestinal

Gastric Adenocarcinoma

NCT06717711 2024-12-05

RCT_LiESWT

Regina Elena Cancer Institute

Phase 3 Recruiting
158 enrolled
Genitourinary

Prostatic Neoplasms, Urogenital Neoplasms

NCT05558007 2024-10-22

Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients

Biozeus Biopharmaceutical S.A.

Phase 2 Recruiting
72 enrolled
Genitourinary

Erectile Dysfunction, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡